Evaluating the endometabolic and bone health effects of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukaemia: a systematic review protocol

INTRODUCTION: Chronic Myeloid Leukaemia (CML) constitutes 15% of new adult leukaemia cases as well as 2%–3% of leukaemia in children under 15% and 9% of leukaemias in adolescents 15–19 years of age annually. The introduction of Tyrosine Kinase Inhibitors (TKI) therapy has dramatically improved survi...

Descripción completa

Detalles Bibliográficos
Autores principales: Balakumaran, Janatani, Birk, Tanisha, Golemiec, Breanne, Helmeczi, Wryan, Inkaran, Jeyanth, Kao, Yun-ya, Leigh, Jennifer, Saliba, Sarah, Sharma, Rishi, Spatafora, Laura, Wright, Kristin, Yao, William, Hillis, Christopher, Banfield, Laura, Thabane, Lehana, Athale, Uma, Samaan, M Constantine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6738716/
https://www.ncbi.nlm.nih.gov/pubmed/31511287
http://dx.doi.org/10.1136/bmjopen-2019-030092

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6738716/
https://www.ncbi.nlm.nih.gov/pubmed/31511287
http://dx.doi.org/10.1136/bmjopen-2019-030092

Ejemplares similares